Latest Payments News

Associate Global Partners Limited reported a 4.6% increase in funds under management to $1.464 billion for Q3 2025, driven by robust inflows and standout returns from its WCM strategies. The company also sustained positive operating cash flows for the fourth consecutive quarter.

Albion Resources has delivered promising results from its maiden drilling campaign at Yandal West, revealing multiple high-grade gold zones and new target corridors that set the stage for an expanded exploration push.

FIN Resources Limited has executed a binding agreement to acquire the fully permitted, high-grade Cabin Lake Gold Project in Canada’s Northwest Territories, setting the stage for immediate exploration and resource growth.

Great Southern Mining has sold a key mining license to Regis Resources for up to A$9 million and is progressing multiple drilling programs across its Australian projects, supported by government grants and a strategic alliance.

Cue Energy Resources reported steady production with notable gains at Mahato and Maari fields, alongside a new gas supply deal and a $3.5 million dividend payment.

Zimi Limited reported a remarkable 367% increase in quarterly revenue alongside a successful $1.85 million capital raise and completion of its manufacturing relocation, setting the stage for accelerated growth in the smart home IoT sector.

Skylark Minerals has completed initial fieldwork at its Simon Copper Project in Mt Isa and launched a new rare-earths desktop study in Brazil, while actively pursuing new gold assets and re-engaging on its Greenland zinc project.

Boss Energy Limited reported a solid cash flow performance for the September 2025 quarter, ending with nearly A$48 million in unrestricted cash, underpinning its ongoing uranium exploration and development activities.

Doctor Care Anywhere reports a 7.5% rise in consultations excluding secondary care and sustains positive cashflow for the second consecutive quarter, reaffirming ambitious medium-term growth targets.

Amplia Therapeutics reports encouraging interim results for narmafotinib in metastatic pancreatic cancer, alongside a successful capital raise and key patent allowance.

Carlton Investments reported a slight rise in net profit and an 8.7% increase in dividends for FY2025, while its investment portfolio grew nearly 60% over five years despite recent market fluctuations.

Dimerix Limited reports solid progress in its Phase 3 trial for DMX-200 targeting rare kidney disease FSGS, backed by orphan drug status in Japan and a robust cash position. The company prepares to engage the FDA on new data supporting regulatory approval.